Multimeric Biotherapeutics, Inc.

MegaLigand image


Richard S. Kornbluth, M.D., Ph.D.

President and Chief Scientific Officer

Dr. Kornbluth invented the company’s technology while serving as Associate Professor of Medicine at the University of California San Diego (UCSD). He is both a basic scientist and a Board Certified medical internist and pulmonary specialist. During an immunology postdoctoral fellowship at The Scripps Research Institute (TNFSF), he filed his first patent on what is now known as CD40 ligand (CD40L). At UCSD, he published more than 50 papers on the immunology and molecular virology of HIV, and wrote or co-wrote 26 funded grant applications. Dr. Kornbluth received a Bachelor’s degree from Harvard College, M.D. from New York Medical College, and Ph.D. in Pathology from Columbia University.
Richard Kornbluth photo

David A. Roth, Ph.D.

Chief Operating Officer

Dr. Roth has extensive biotechnology management experience, including product and business development and research operations experience. He was most recently Senior Director - Research Operations at Halozyme Therapeutics, Inc. where he directed teams that generated several registered products. Prior to that, he was Senior Vice President for R&D at CODA Genomics (now Verdezyne, Inc.). He is the author of 36 papers and 26 patents. Dr. Roth received his B.S., M.S., and Ph.D. degrees from the University of California at Berkeley, and took postdoctoral training at UCSD School of Medicine.
Photo of David Roth

Marc Hertz, Ph.D.
Chair of the Board

Dr. Herz was previously CEO of Pharmexa, Inc. (formerly Epimmune, Inc.), a wholly owned subsidiary of Pharmexa A/S (CSE: PHARMX) that developed vaccines and cancer immunotherapies. At Pharmexa, he was responsible for 28 scientists and administrators and directed company strategy, business development, and investor relations. Dr. Hertz participated in multiple rounds of public fundraising that generated approximately $90 million in investments for the company. Marc received a Bachelor’s degree from Bowdoin College and his Ph.D. in Immunology from the University of Colorado Health Sciences Center and the National Jewish Medical and Research Center. Marc Hertz photo